Drawing for LAILA

USPTO serial 99231504

LAILA

Reviewed by CopyMark Law Group

Status 653
Filing date
Status date
Registration date
—
Examiner
BECKER, JOSEPH RAPHAEL
Law office
TMO LAW OFFICE 122

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with LAILA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

John Paul Oleksiuk

John Paul Oleksiuk Cooley LLP1299 Pennsylvania Avenue, NW, Suite 700Washington, DC 20004United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for detecting and treating cancer, infectious diseases, inflammation, fibrosis, hypertension, cardiovascular disease, chronic obstructive pulmonary disease, obesity, and musculoskeletal diseases; Pharmaceutical peptide and protein compositions for detecting and treating cancer, infectious diseases, inflammation, fibrosis, hypertension, cardiovascular disease, chronic obstructive pulmonary disease, obesity, and musculoskeletal diseases; Protein arrays for medical diagnosis purposes; Pharmaceutical preparations in the nature of therapeutic proteins for use in the detection and treatment of human diseasesACTIVE—
042scientific research in the field of proteomics; pharmaceutical drug development services; pharmaceutical research services; provision of information and data relating to medical and pharmaceutical research and development; medical research; biological researchACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 28, 2026RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Apr 30, 2026GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Apr 30, 2026GNSLLETTER OF SUSPENSION E-MAILED—
Apr 30, 2026CNSLSUSPENSION LETTER WRITTEN—
Apr 29, 2026TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 29, 2026CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 29, 2026TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 23, 2026XELGAPPLICATION EXTENSION GRANTED/RECEIPT PROVIDED—
Jan 23, 2026XELRAPPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED—
Nov 1, 2025GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 1, 2025GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 1, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 1, 2025DOCKASSIGNED TO EXAMINER—
Oct 19, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 12, 2025MAFRAPPLICATION FILING RECEIPT MAILED—
Jun 12, 2025NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance